Brokerages Expect Curis, Inc. (CRIS) Will Post Quarterly Sales of $2.03 Million

Wall Street brokerages expect Curis, Inc. (NASDAQ:CRIS) to report sales of $2.03 million for the current quarter, Zacks reports. Two analysts have provided estimates for Curis’ earnings, with estimates ranging from $1.90 million to $2.15 million. Curis posted sales of $2.36 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 14%. The firm is scheduled to issue its next quarterly earnings results on Thursday, March 8th.

On average, analysts expect that Curis will report full-year sales of $2.03 million for the current year, with estimates ranging from $8.50 million to $8.79 million. For the next financial year, analysts expect that the company will post sales of $9.69 million per share, with estimates ranging from $8.97 million to $10.40 million. Zacks’ sales averages are an average based on a survey of research firms that cover Curis.

Curis (NASDAQ:CRIS) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.02). Curis had a negative net margin of 629.29% and a negative return on equity of 250.58%. The company had revenue of $2.44 million during the quarter, compared to analyst estimates of $2.19 million. During the same quarter last year, the business earned ($0.21) EPS. The firm’s revenue for the quarter was up 38.6% compared to the same quarter last year.

CRIS has been the topic of several research reports. BidaskClub downgraded shares of Curis from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. ValuEngine raised shares of Curis from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Zacks Investment Research downgraded shares of Curis from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. Finally, Guggenheim initiated coverage on shares of Curis in a research note on Monday, October 23rd. They issued a “buy” rating and a $7.00 price target on the stock. Three investment analysts have rated the stock with a sell rating and three have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $6.50.

In other news, CEO Ali Ph.D. Fattaey bought 50,000 shares of Curis stock in a transaction on Wednesday, November 15th. The shares were bought at an average cost of $1.06 per share, with a total value of $53,000.00. Following the completion of the purchase, the chief executive officer now directly owns 115,890 shares of the company’s stock, valued at $122,843.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.07% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. increased its position in shares of Curis by 1.6% during the second quarter. Goldman Sachs Group Inc. now owns 119,638 shares of the biotechnology company’s stock valued at $226,000 after acquiring an additional 1,880 shares during the last quarter. Rhumbline Advisers increased its position in shares of Curis by 1.9% during the second quarter. Rhumbline Advisers now owns 127,529 shares of the biotechnology company’s stock valued at $241,000 after acquiring an additional 2,340 shares during the last quarter. American International Group Inc. grew its holdings in shares of Curis by 7.1% in the first quarter. American International Group Inc. now owns 68,733 shares of the biotechnology company’s stock valued at $191,000 after purchasing an additional 4,560 shares in the last quarter. Metropolitan Life Insurance Co. NY grew its holdings in shares of Curis by 9.3% in the first quarter. Metropolitan Life Insurance Co. NY now owns 90,156 shares of the biotechnology company’s stock valued at $251,000 after purchasing an additional 7,638 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Curis by 8.8% in the second quarter. The Manufacturers Life Insurance Company now owns 100,023 shares of the biotechnology company’s stock valued at $190,000 after purchasing an additional 8,102 shares in the last quarter. Institutional investors and hedge funds own 46.88% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Brokerages Expect Curis, Inc. (CRIS) Will Post Quarterly Sales of $2.03 Million” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/11/21/brokerages-expect-curis-inc-cris-will-post-quarterly-sales-of-2-03-million.html.

Curis (CRIS) traded down $0.01 during trading hours on Friday, hitting $0.88. 1,643,580 shares of the stock traded hands, compared to its average volume of 698,617. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 1.24. Curis has a 12-month low of $0.86 and a 12-month high of $3.48.

About Curis

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Get a free copy of the Zacks research report on Curis (CRIS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply